Literature DB >> 7912177

Effect of cimetidine, probenecid, and ketoconazole on the distribution, biliary secretion, and metabolism of [3H]taxol in the Sprague-Dawley rat.

R W Klecker1, C A Jamis-Dow, M J Egorin, K Erkmen, R J Parker, R Stevens, J M Collins.   

Abstract

Male Sprague-Dawley rats had their bile ducts cannulated and were dosed with [3H]taxol (2 mg/kg, 68-77 microCi/mg) as a continuous intravenous infusion for 6 hr so that the plasma concentrations, tissue distribution, metabolism, and biliary secretion of taxol could be studied. Defining potential drug-drug interactions of taxol with cimetidine (90 mg/kg), probenecid (360 mg/kg), and ketoconazole (50 mg/kg) was motivated by frequent concomitant clinical use or the potential to reduce clearance of taxol so that lower doses could be used. At 6 hr, rats were killed. Samples of blood (plasma), lung, spleen, liver, kidney, heart, skeletal muscle, brain, testes, and fat were obtained. Taxol and metabolites were measured by total radioactivity counting and HPLC separation using on-line radioactivity detection. Concentrations of taxol in plasma increased to 0.19 microM in the control rats and did not reach steady-state by 6 hr. Lung, spleen, liver, and kidneys had the greatest tissue taxol concentrations [4.7-5.7 nmol/g (microM)] and were > 25-fold higher than the simultaneous 6-hr plasma taxol concentration. Taxol concentrations in brain and testes were negligible, 0.06 and 0.07 nmol/g, respectively. Radioactive metabolites were not found in plasma or most tissues. Only liver had appreciable concentrations of taxol and metabolites; however, > 80% of hepatic radioactivity was parent taxol. Through 6 hr of collection, 24% of the dose was secreted in the bile approximately 38% of which was as parent taxol. Cimetidine had no effect on the distribution, metabolism, or elimination of [3H]taxol. Probenecid did not effect tissue distribution or plasma concentrations of taxol.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7912177

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  8 in total

Review 1.  Interactions between antiretrovirals and antineoplastic drug therapy.

Authors:  Tony Antoniou; Alice L Tseng
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

2.  Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats.

Authors:  Salvatore Cisternino; Fanchon Bourasset; Yves Archimbaud; Dorothée Sémiond; Gérard Sanderink; Jean-Michel Scherrmann
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

3.  Enhanced oral bioavailability of paclitaxel by coadministration of the P-glycoprotein inhibitor KR30031.

Authors:  Jong Soo Woo; Chang Hyun Lee; Chang Koo Shim; Sung-Joo Hwang
Journal:  Pharm Res       Date:  2003-01       Impact factor: 4.200

4.  Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice.

Authors:  J L Eiseman; N D Eddington; J Leslie; C MacAuley; D L Sentz; M Zuhowski; J M Kujawa; D Young; M J Egorin
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Metabolism of taxol by human and rat liver in vitro: a screen for drug interactions and interspecies differences.

Authors:  C A Jamis-Dow; R W Klecker; A G Katki; J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

Review 6.  Clinical pharmacokinetics of paclitaxel.

Authors:  D S Sonnichsen; M V Relling
Journal:  Clin Pharmacokinet       Date:  1994-10       Impact factor: 6.447

7.  The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study.

Authors:  G J Lesser; S A Grossman; S Eller; E K Rowinsky
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Pharmacokinetic Alteration of Paclitaxel by Ferulic Acid Derivative.

Authors:  Jaeok Lee; Song Wha Chae; LianJi Ma; So Yeon Lim; Sarah Alnajjar; Hea-Young Park Choo; Hwa Jeong Lee; Sandy Jeong Rhie
Journal:  Pharmaceutics       Date:  2019-11-09       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.